AR130467A1 - PHENALKYLAMINES AND METHODS FOR MANUFACTURING AND USING THE SAME - Google Patents
PHENALKYLAMINES AND METHODS FOR MANUFACTURING AND USING THE SAMEInfo
- Publication number
- AR130467A1 AR130467A1 ARP230102426A ARP230102426A AR130467A1 AR 130467 A1 AR130467 A1 AR 130467A1 AR P230102426 A ARP230102426 A AR P230102426A AR P230102426 A ARP230102426 A AR P230102426A AR 130467 A1 AR130467 A1 AR 130467A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- composition
- formula
- treating
- administering
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 7
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 15
- 239000000203 mixture Substances 0.000 abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 abstract 6
- 208000020016 psychiatric disease Diseases 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 208000027109 Headache disease Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 230000004410 intraocular pressure Effects 0.000 abstract 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente divulgación proporciona compuestos de fenalquilamina y su uso en el tratamiento de trastornos médicos, tales como enfermedades y trastornos psiquiátricos. Se proporcionan composiciones farmacéuticas y métodos para preparar diversos compuestos de fenalquilamina. También se divulgan en el presente documento métodos para tratar una enfermedad o trastorno psiquiátrico que comprenden administrar a un paciente que lo necesita una cantidad terapéuticamente eficaz de cualquiera de los compuestos terapéuticos descritos en el presente documento o una composición farmacéutica que contiene el compuesto terapéutico. Reivindicación 1: Una composición que comprende un compuesto que tiene la siguiente estructura enantiomérica R: de fórmula (1) en donde la composición incluye opcionalmente el compuesto enantiomérico S de fórmula (1), siempre que el compuesto enantiomérico R de fórmula (1) esté en exceso enantiomérico, o el compuesto de fórmula (1) esté en forma enantioméricamente pura en la composición; y sales farmacéuticamente aceptables del compuesto. Reivindicación 4: Un compuesto que tiene la siguiente estructura: de fórmula (2) en donde: Rᵃ se selecciona del grupo que consiste en -CH₂CF₃, -CF₂CH₃ y -CF₂CF₃; y sales farmacéuticamente aceptables del mismo. Reivindicación 8: Un compuesto que tiene la siguiente estructura: de fórmula (3) en donde: Rᵇ es -CH₂CD₃ o -CD₂CD₃; y sales farmacéuticamente aceptables del mismo. Reivindicación 16: Un método para tratar una enfermedad o trastorno psiquiátrico, que comprende administrar a un paciente que lo necesita una cantidad terapéuticamente eficaz de una composición o compuesto de cualquiera de las reivindicaciones 1 - 14 o una composición farmacéutica de la reivindicación 15. Reivindicación 24: Un método para tratar un dolor de cabeza o un trastorno de dolor de cabeza, que comprende administrar a un paciente que lo necesita una cantidad terapéuticamente eficaz de una composición o compuesto de cualquiera de las reivindicaciones 1 - 14 o una composición farmacéutica de la reivindicación 15. Reivindicación 25: Un método para tratar una enfermedad o trastorno inflamatorio, que comprende administrar a un paciente que lo necesita una cantidad terapéuticamente eficaz de una composición o compuesto de cualquiera de las reivindicaciones 1 - 14 o una composición farmacéutica de la reivindicación 15. Reivindicación 26: Un método para tratar la presión intraocular alta, que comprende administrar a un paciente que lo necesita una cantidad terapéuticamente eficaz de una composición o compuesto de cualquiera de las reivindicaciones 1 - 14 o una composición farmacéutica de la reivindicación 15.The present disclosure provides phenalkylamine compounds and their use in treating medical disorders, such as psychiatric diseases and disorders. Pharmaceutical compositions and methods for preparing various phenalkylamine compounds are provided. Also disclosed herein are methods for treating a psychiatric disease or disorder comprising administering to a patient in need thereof a therapeutically effective amount of any of the therapeutic compounds described herein or a pharmaceutical composition containing the therapeutic compound. Claim 1: A composition comprising a compound having the following R enantiomeric structure: of formula (1) wherein the composition optionally includes the S enantiomeric compound of formula (1), provided that the R enantiomeric compound of formula (1) is in enantiomeric excess, or the compound of formula (1) is in enantiomerically pure form in the composition; and pharmaceutically acceptable salts of the compound. Claim 4: A compound having the following structure: of formula (2) wherein: Rᵃ is selected from the group consisting of -CH₂CF₃, -CF₂CH₃ and -CF₂CF₃; and pharmaceutically acceptable salts thereof. Claim 8: A compound having the following structure: of formula (3) wherein: Rᵇ is -CH₂CD₃ or -CD₂CD₃; and pharmaceutically acceptable salts thereof. Claim 16: A method of treating a psychiatric disease or disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a composition or compound of any of claims 1 - 14 or a pharmaceutical composition of claim 15. Claim 24: A method of treating a headache or headache disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a composition or compound of any of claims 1 - 14 or a pharmaceutical composition of claim 15. Claim 25: A method of treating an inflammatory disease or disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a composition or compound of any of claims 1 - 14 or a pharmaceutical composition of claim 15. Claim 26: A method of treating high intraocular pressure, comprising administering to a patient in need thereof a therapeutically effective amount of a composition or compound of any of claims 1 - 14 or a pharmaceutical composition of claim 15. pharmaceutical of claim 15.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263405782P | 2022-09-12 | 2022-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130467A1 true AR130467A1 (en) | 2024-12-11 |
Family
ID=90275706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102426A AR130467A1 (en) | 2022-09-12 | 2023-09-12 | PHENALKYLAMINES AND METHODS FOR MANUFACTURING AND USING THE SAME |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR130467A1 (en) |
| TW (1) | TWI854832B (en) |
| WO (2) | WO2024059090A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4034113A (en) * | 1975-04-09 | 1977-07-05 | Shulgin Alexander T | Treatment of senile geriatric patients to restore performance |
| TW200744567A (en) * | 2005-09-23 | 2007-12-16 | Alcon Inc | Phenylethylamine analogs and their use for treating glaucoma |
| US8877794B2 (en) * | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US12534425B2 (en) * | 2020-06-29 | 2026-01-27 | Gilgamesh Pharmaceuticals, Inc. | Phenalkylamines and methods of treating mood disorders |
| MX2023010711A (en) * | 2021-03-12 | 2023-11-10 | Gilgamesh Pharmaceuticals Inc | Phenalkylamines and methods of making and using the same. |
-
2023
- 2023-09-12 WO PCT/US2023/032570 patent/WO2024059090A1/en not_active Ceased
- 2023-09-12 AR ARP230102426A patent/AR130467A1/en unknown
- 2023-09-12 WO PCT/US2023/032450 patent/WO2024059017A2/en not_active Ceased
- 2023-09-12 TW TW112134682A patent/TWI854832B/en active
Also Published As
| Publication number | Publication date |
|---|---|
| TW202421103A (en) | 2024-06-01 |
| WO2024059017A3 (en) | 2024-06-27 |
| WO2024059090A1 (en) | 2024-03-21 |
| TWI854832B (en) | 2024-09-01 |
| WO2024059017A2 (en) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023030072A (en) | combination therapy | |
| DOP2025000250A (en) | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | |
| CL2020002562A1 (en) | (divisional application 1097-2020) pyridinecarbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors. | |
| JP2008520589A5 (en) | ||
| JP2021165285A (en) | Ophthalmic composition | |
| AR128717A1 (en) | SOLID FORMS, SALTS AND PREPARATION PROCESSES OF A CDK2 INHIBITOR | |
| CO2025003099A2 (en) | Compounds for cancer treatment | |
| CO2024017138A2 (en) | Amidoheteroaromatic compounds useful in the treatment of liver diseases | |
| CL2025000161A1 (en) | Cyclic compounds and methods of using same. | |
| KR20160005356A (en) | Radiomitigating pharmaceutical formulations | |
| AR130472A1 (en) | APX3330 SALTS AND ESTERS, AND THERAPEUTICAL USES THEREOF | |
| AR130467A1 (en) | PHENALKYLAMINES AND METHODS FOR MANUFACTURING AND USING THE SAME | |
| MX2025008207A (en) | Stereoisomer and deuterated derivative of pyrazoloquinazoline compound and use | |
| MX2023015016A (en) | Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application. | |
| AR128100A1 (en) | COMPOUNDS FOR THE TREATMENT OF HAIR LOSS | |
| MX2023011518A (en) | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USES. | |
| AR126835A1 (en) | DEUTERATED ANALOGS AND DERIVATIVES OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE AND USES OF THESE | |
| AR048929A1 (en) | DOSAGE FORMS AND TREATMENT METHODS USING VEGFR INHIBITORS. | |
| AR134195A1 (en) | HETEROARYL ESTER DERIVATIVES AS SODIUM CHANNEL INHIBITORS | |
| AR134196A1 (en) | HETEROARYL AMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | |
| HK40004468B (en) | Combination therapy | |
| RU2008112310A (en) | COMPOUND OF THIOMORPHOLINE AND METHOD OF ITS PRODUCTION | |
| AR133249A1 (en) | NEW COMPOUNDS | |
| CL2025001386A1 (en) | Hexahydropyrano[3',4':4,5]pyrrolo[2,3-d]pyrimidine derivatives and use in treating cancer. | |
| AR132862A1 (en) | METHODS FOR THE TREATMENT OF DERMATOMYOSITIS WITH BREPOCITINIB |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |